Positioning
China's new national pharmaceutical force
As a high-end R&D and manufacturing platform for Modified Release formulation, the company focuses on the research and development, production, and sales of advanced micro-pellet coating such as osmotic pumps, pellet coatings, and skeleton tablets. It has passed multiple cGMP on-site inspections by the US FDA, achieving FDA "zero defect" certification twice, and multiple products have achieved co production, reporting, and sales in China and the United States.
Qingdao BAHEAL pharmaceutical Co.,Ltd.(referred to as "Qingdao Baheal Pharma"), formerly known as Qingdao Second Pharmaceutical Factory, has a long history of more than 60 years. It is now a subsidiary of listed company Baheal Medical (SZ. 301015), located at No. 88 Taiji Road, Jimo District, Qingdao, with a total area of approximately 128 acres (85600 square meters).
The company is the first formulation enterprise in Qingdao to pass the FDA inspection in the United States. It has successively won honors such as Shandong Gazelle Enterprise, High tech Enterprise, Qingdao Innovative Small and Medium sized Enterprise, Qingdao Specialized, Refined, Unique and New Small and Medium sized Enterprise, ISPE Best Facility Management Award, Qingdao Delayed and Controlled Release Solid Formulation Technology Innovation Center, Jimo Solid Formulation Delayed and Controlled Release Engineering Technology Research Center, etc. It has also passed the certification of the two integration management system and Qingdao high-end delayed and controlled release formulation digital workshop.
Multiple products developed by the company have been awarded research projects for the National "Thirteenth Five Year Plan" Major New Drug Creation Science and Technology Major Special Project, the Shandong Provincial Department of Science and Technology Major Science and Technology Innovation Engineering Project, and the Qingdao Science and Technology Plan Independent Innovation Key Project.
In the future, Qingdao Bahealpharma will continue to deepen its cultivation in the field of high-end sustained-release drugs. Through technological innovation, it will continuously develop and optimize innovative products for medical scenarios, bringing international quality high-end drug formulations to Chinese and foreign patients.
+year
production experience
㎡
covers an area of
+item
for letters patent are
+
Number of cooperative customers
Baheal Pharma is an innovative pharmaceutical company specializing in the research and development of modern and slow-release formulations of traditional Chinese medicine. It is a controlling subsidiary of Baheal Medical (SZ. 301015). Adhering to the principle of "international quality, caring for health", the company takes independent research and development as its core, modern medical theory as its guidance, and high-end sustained-release formulation technology as its characteristic, to create innovative Chinese and Western medicine products with independent intellectual property rights。
In the field of modern traditional Chinese medicine production, based on the concept of disease diagnosis, quality control, and proven efficacy, Baheal Pharma has built a complete modern industrial chain of traditional Chinese medicine from medicinal herb planting and processing, extraction to finished product formulation and commercialization. It has more than 10 self owned traditional Chinese medicine planting bases in 8 provinces, and has established DNA and fingerprint archives and traceable information systems for original medicinal herbs, creating an international standard modern compound Chinese medicine production platform. In the field of chemical drug production, the company focuses on high-end formulation technologies with high barriers such as research and development of osmotic pump controlled release dosage forms. The related research and development has been selected for the national "Thirteenth Five Year Plan Major New Drug Creation Science and Technology Special Project". The production platform has repeatedly passed the cGMP on-site inspection of the US FDA with "zero defects", and the products have achieved co production, reporting, and sales between China and the United States。
The company has achieved innovative breakthroughs in multiple treatment fields such as liver disease and metabolic diseases, and has established an international, standardized, and modern R&D and production system for traditional Chinese and Western medicine. With two major R&D and production bases in Shanghai and Qingdao, the company can provide one-stop CMO/CDMO services from pharmaceutical research, process development, registration and application to production, manufacturing, and commercialization。
To better serve human health, Baheal Pharma is working with national research institutions to build a research cooperation platform, focusing on breakthroughs in the treatment of difficult to treat diseases and continuously providing international quality drugs to global consumers。
China's new national pharmaceutical force
Our mission is to deliver better brand commercialization platform and services to the whole society, and to help optimize health industry resource allocation. We are dedicated to driving pharmaceutical innovation and improving the well beings of our employees.
Bodhi Attain Health
People-oriented, respect for sciences, accountable, open minded and collaborative, perseverant and confident.
Technological innovation, quality first, continuous improvement Safe and effective, honest and realistic, customer satisfaction
We can succeed because we are united, we are diligent, we constantly reflect on ourselves!